現在 JavaScriptが無効になっています。
Yahoo!ファイナンスのすべての機能を利用するためには、JavaScriptの設定を有効にしてください。
JavaScriptの設定を変更する方法はこちら。

NASDAQ

シアトル・ジェネティクス

SGEN

---

15分ディレイ株価
--:--
（現地時刻: --:--）

ポートフォリオに追加

シアトル・ジェネティクスの掲示板の投稿コメント詳細

投稿コメント一覧へ戻る

kaz*ヒト投与可能で一斉摘発ｗ

No.22017/8/1 7:57

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab vedotin (Adcetris®; Seattle Genetics) as post-autologous stem cell transplant (ASCT) consolidation treatment of patients with Hodgkin lymphoma (HL) at increased risk of relapse or progression.

In 2013 Health Canada granted brentuximab vedotin approval with conditions for relapsed or refractory Hodgkin lymphoma and sALCL, and non-conditional approval for post-ASCT consolidation treatment of Hodgkin lymphoma patients at increased risk of relapse or progression.

返信

投資の参考になりましたか？

返信コメント

kaz*ヒト投与可能で一斉摘発ｗ
No.32017/8/1 7:58
>>2
Brentuximab vedotin is an antibody-drug conjugate or ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.

The drug is used in the treatment of lymphoma, a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.
返信
投資の参考になりましたか？

投稿コメント一覧へ戻る

【PR】堅調な伸びを続ける「米国株」について学ぼう！高配当などおすすめ銘柄や選び方は？ - マネックス証券 - Yahoo!ファイナンス